Biointaxis is an academic Biotech spin-off established in 2018 from the Health Sciences Research Institute Germans Trias i Pujol (IGTP), located in Badalona, Barcelona, Spain, to translate scientific knowledge into the development and implementation of effective therapies for patients suffering from rare neurological diseases. Biointaxis scientists are currently developing a gene therapy treatment for Friedreich´s ataxia, a rare inherited, progressive, neurodegenerative disease that typically affects teenagers and young adults. Biointaxis’ research shows an excellent safety profile and treatment efficacy, enabling the restoration of neurological functions and cardiac deficits in animal models of Friedreich´s ataxia.
Biointaxis participates in the PHOENIX project by validating the μHeart and μNMC systems developed by Consortium members of the PHOENIX project with focus on its potential use in the development of gene therapies by generating robust phenotypic efficacy and safety preclinical data by using our FRDA models (both cardiac and neuronal and BTX-101 (FRATAXAV), a new patented gene therapy designed for the curative treatment of FRDA. Furthermore, disease biomarkers identified by Biointaxis scientists will assessed in BTX-101 treated compared with non-treated FRDA models relative to the restoration of functionalities and these data will be contrasted with data previously collected by BIOINTAXIS from different animal models treated with the same therapy. These investigations will contribute by enhancing the cost/benefit value of μHeart and μNMC and its use compared with existing preclinical models for gene therapy development.
Main contributions and activities:
Antoni Matilla-Dueñas, PhD – General Director
Ivelisse Sanchez, PhD – Scientific Director
